Logo image of ADMP

ADAMIS PHARMACEUTICALS CORP (ADMP) Stock Fundamental Analysis

NASDAQ:ADMP - Nasdaq - US00547W3079 - Common Stock - Currency: USD

0.7751  +0.01 (+0.86%)

After market: 0.77 -0.01 (-0.66%)

Fundamental Rating

1

Taking everything into account, ADMP scores 1 out of 10 in our fundamental rating. ADMP was compared to 195 industry peers in the Pharmaceuticals industry. ADMP may be in some trouble as it scores bad on both profitability and health. ADMP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADMP has reported negative net income.
ADMP had a negative operating cash flow in the past year.
In the past 5 years ADMP always reported negative net income.
In the past 5 years ADMP always reported negative operating cash flow.
ADMP Yearly Net Income VS EBIT VS OCF VS FCFADMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

The profitability ratios for ADMP are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADMP Yearly ROA, ROE, ROICADMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADMP Yearly Profit, Operating, Gross MarginsADMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

More info and screens

1

2. Health

2.1 Basic Checks

ADMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADMP has about the same amount of shares outstanding.
ADMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADMP Yearly Shares OutstandingADMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M
ADMP Yearly Total Debt VS Total AssetsADMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -115.24, we must say that ADMP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -115.24, ADMP is doing worse than 97.60% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -115.24
ROIC/WACCN/A
WACC8.93%
ADMP Yearly LT Debt VS Equity VS FCFADMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

ADMP has a Current Ratio of 0.23. This is a bad value and indicates that ADMP is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ADMP (0.23) is worse than 94.71% of its industry peers.
ADMP has a Quick Ratio of 0.23. This is a bad value and indicates that ADMP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.19, ADMP is not doing good in the industry: 95.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.19
ADMP Yearly Current Assets VS Current LiabilitesADMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.47% over the past year.
The Revenue has grown by 700.00% in the past year. This is a very strong growth!
Measured over the past years, ADMP shows a very negative growth in Revenue. The Revenue has been decreasing by -18.29% on average per year.
EPS 1Y (TTM)40.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.18%
Revenue 1Y (TTM)700%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%120%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADMP Yearly Revenue VS EstimatesADMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
ADMP Yearly EPS VS EstimatesADMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADMP Price Earnings VS Forward Price EarningsADMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADMP Per share dataADMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ADMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAMIS PHARMACEUTICALS CORP

NASDAQ:ADMP (9/7/2023, 8:00:00 PM)

After market: 0.77 -0.01 (-0.66%)

0.7751

+0.01 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-08 2023-08-08/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners95.51%
Ins Owner Change0%
Market Cap2.16M
Analysts43.33
Price Target0.43 (-44.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.83
FCFYN/A
OCF(TTM)-4.72
OCFYN/A
SpS1.84
BVpS-4.12
TBVpS-4.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.93%
Cap/Sales 5.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.23
Quick Ratio 0.19
Altman-Z -115.24
F-Score4
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)52.33%
Cap/Depr(5y)73.76%
Cap/Sales(3y)34.55%
Cap/Sales(5y)28.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)700%
Revenue growth 3Y-40.07%
Revenue growth 5Y-18.29%
Sales Q2Q%120%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y60.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.92%
OCF growth 3YN/A
OCF growth 5YN/A